Ava Lifescience Gmbh

Marcus Dühren-Von Minden

Holger Klapproth

The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21). The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Antibodies targeting the B-cell receptor of chronic lymphocytic leukemia and uses thereof

The present invention relates to the field of producing, identifying, and selecting biological binding molecules, e.g. in particular antibodies or fragments thereof, which selectively bind to somatically hypermutated B-cell receptors or B-cell receptor complexes. The method is used in order to select a biological binding molecule which specifically binds to a B-cell receptor having hypermutated regions as the target receptor, but not to a B-cell receptor without hypermutated regions, and is carried out in a cell-based system using immature B cells which are in the pro/pre stage and cause a 'Triple Knockout' of the genes for RAG2 or RAG1, Lambda5, and SLP65.

Growing community of inventors

Müllheim, Germany

Marcus Dühren-Von Minden